TG Therapeutics (TGTX) Tops Q2 EPS by 21c

TG Therapeutics (NASDAQ: TGTX) reported Q2 EPS of ($0.30), $0.21 better than the analyst estimate of ($0.51). Revenue for the quarter came in at $594 thousand versus the consensus estimate of $175.43 thousand.

For earnings history and earnings-related data on TG Therapeutics (TGTX) click here.

You May Also Be Interested In

• Amphenol (APH) Tops Q1 EPS by 7c, offers guidance
• Greene County Bancorp, Inc. (GCBC) Reports Q3 EPS of $0.34
• Hasbro (HAS) brand strength sees earnings top expectations